Rice Hall James & Associates LLC Increases Stake in Collegium Pharmaceutical Inc (NASDAQ:COLL)

Rice Hall James & Associates LLC boosted its position in shares of Collegium Pharmaceutical Inc (NASDAQ:COLL) by 5.8% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 1,260,690 shares of the specialty pharmaceutical company’s stock after purchasing an additional 69,549 shares during the quarter. Rice Hall James & Associates LLC owned about 3.78% of Collegium Pharmaceutical worth $16,578,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the stock. MERIAN GLOBAL INVESTORS UK Ltd purchased a new stake in Collegium Pharmaceutical during the 1st quarter valued at about $26,000. First Quadrant L P CA lifted its stake in Collegium Pharmaceutical by 87.2% during the 2nd quarter. First Quadrant L P CA now owns 4,484 shares of the specialty pharmaceutical company’s stock valued at $59,000 after acquiring an additional 2,089 shares during the period. DekaBank Deutsche Girozentrale lifted its stake in Collegium Pharmaceutical by 22.2% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 13,200 shares of the specialty pharmaceutical company’s stock valued at $221,000 after acquiring an additional 2,400 shares during the period. Sheaff Brock Investment Advisors LLC lifted its stake in Collegium Pharmaceutical by 14.9% during the 1st quarter. Sheaff Brock Investment Advisors LLC now owns 20,650 shares of the specialty pharmaceutical company’s stock valued at $313,000 after acquiring an additional 2,675 shares during the period. Finally, Bank of America Corp DE lifted its stake in Collegium Pharmaceutical by 17.2% during the 4th quarter. Bank of America Corp DE now owns 23,981 shares of the specialty pharmaceutical company’s stock valued at $412,000 after acquiring an additional 3,525 shares during the period. 96.29% of the stock is currently owned by institutional investors.

In other news, CEO Joseph Ciaffoni sold 7,436 shares of the stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $11.59, for a total value of $86,183.24. Following the transaction, the chief executive officer now owns 190,755 shares in the company, valued at approximately $2,210,850.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Scott Dreyer sold 2,857 shares of the stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $12.31, for a total transaction of $35,169.67. Following the completion of the transaction, the executive vice president now owns 40,596 shares in the company, valued at approximately $499,736.76. The disclosure for this sale can be found here. Insiders sold a total of 66,144 shares of company stock worth $754,506 in the last quarter. Company insiders own 8.08% of the company’s stock.

COLL traded down $0.51 during midday trading on Wednesday, hitting $11.23. 126,066 shares of the company traded hands, compared to its average volume of 377,402. The company has a quick ratio of 1.20, a current ratio of 1.25 and a debt-to-equity ratio of 0.23. The firm has a market cap of $392.94 million, a price-to-earnings ratio of -9.44 and a beta of 0.54. The firm has a 50-day moving average of $11.53. Collegium Pharmaceutical Inc has a 52 week low of $10.01 and a 52 week high of $19.83.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Wednesday, August 7th. The specialty pharmaceutical company reported ($0.14) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.05. Collegium Pharmaceutical had a negative net margin of 7.45% and a negative return on equity of 26.10%. The firm had revenue of $75.04 million for the quarter, compared to analysts’ expectations of $75.77 million. During the same quarter in the prior year, the business earned ($0.40) EPS. The business’s quarterly revenue was up 2.7% on a year-over-year basis. On average, analysts expect that Collegium Pharmaceutical Inc will post -0.46 EPS for the current year.

Several research firms have issued reports on COLL. Cantor Fitzgerald restated an “overweight” rating and set a $24.00 target price (down previously from $35.00) on shares of Collegium Pharmaceutical in a research note on Thursday, August 8th. Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Thursday, August 8th. BidaskClub upgraded shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Tuesday. ValuEngine upgraded shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, HC Wainwright began coverage on shares of Collegium Pharmaceutical in a research note on Friday, May 3rd. They set a “buy” rating and a $23.00 target price on the stock. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $24.33.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.

Featured Story: What is the downside to momentum investing?

Institutional Ownership by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.